IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
CSPC will receive an upfront payment of $100 million from AstraZeneca
Our centers are performing as expected or even better
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
These abstracts report on the company's three lead drug candidates, including olverembatinib
Subscribe To Our Newsletter & Stay Updated
